MIRM Q3'26 Earnings: EPS estimate is (0.49) USD

What happened

Mirum Pharmaceuticals is scheduled to report its Q3'26 results on November 03, after the market closes, with disclosure expected at 4:01 PM ET. The supplied estimate is revenue of 178.08 million USD and earnings per share of (0.49) USD.

Confirmed

Global impact / market context

The results will show whether sales meet the 178.08 million USD estimate and whether the reported loss per share is near the expected (0.49) USD. A revenue or earnings gap can change views of the company’s ability to grow sales and manage costs.

Analyst inference

Mirum is scheduled to report after the market closes on November 03. The article gives estimated Q3'26 revenue of 178.08 million USD and earnings per share of (0.49) USD, not reported results. Investors therefore lack confirmed quarterly results; the estimates could shape expectations for revenue and profit until the company reports.

Analyst inference

What to watch

1. Check the Q3'26 report after the market closes on November 03 for actual revenue and earnings per share, then compare both figures with the supplied estimates. Confirmed
2. If revenue falls short of 178.08 million USD or the loss per share exceeds (0.49) USD, assess whether the company identifies higher costs or weaker sales. Analyst inference
3. Look for any company explanation of sales and costs alongside the results; the supplied article does not include management guidance or details about the reasons for its estimates. Analyst inference

Evidence

• Original source link unavailable